Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fibromyalgia clinical design

Executive Summary

The arthritis committee will meet June 23 to discuss clinical trial design for therapies intended to treat fibromyalgia, including important disease endpoints. Pfizer has been conducting studies of its Neurontin successor agent pregabalin in fibromyalgia (1"The Pink Sheet" Nov. 4, 2002, p. 8). The meeting will begin at 8 a.m. on both days at the Holiday Inn in Bethesda, Md. [For 2webcasts, live video or videotapes of these and other meetings, go to FDAAdvisoryCommittee.com]...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS041772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel